Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07089706 · ClinicalTrials.gov registry record · Phase 4
A Study to Evaluate the Immunogenicity and Safety of mRNA-1283 COVID-19 Variant-containing Formulations
A Phase 4 study of COVID-19, sponsored by ModernaTX.
- Recruiting
- Registry status
- Phase 4
- Development phase
- 832
- Enrollment target
- 5
- Study locations
NCT07089706: Recruiting Phase 4 study of COVID-19, sponsored by ModernaTX.
NCT07089706 is a Phase 4 study of COVID-19 that is actively recruiting participants, run by ModernaTX. The registered enrollment target is 832 participants, below the 38,462-participant average among 298 other COVID-19 trials with a reported enrollment target (98% lower). The trial reports 5 study locations across 4 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07089706, a Phase 4 study of COVID-19, is actively recruiting participants, sponsored by ModernaTX.
- RECRUITING
- Registry status
- Phase 4
- Development phase
- 832 participants
- Enrollment target
- 5
- Study locations
Study Summary
The purpose of this study is to evaluate the immunogenicity and safety of the recommended variant-containing formulations of mRNA-1283 COVID-19 vaccine (mNEXSPIKE®) within the current epidemiological environment.
Conditions Studied
Interventions
- BIOLOGICAL mRNA-1283.251 Variant-containing Formulation
Study Locations (5)
Louisiana
- DelRicht Research-Baton Rouge - Baton Rouge
- DelRicht Research-New Orleans - New Orleans
Georgia
- DelRicht Research-Atlanta - Atlanta
Mississippi
- DelRicht Research-Gulfport - Gulfport
Oklahoma
- DelRicht Research-Tulsa - Tulsa
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 832 participants |
| Start Date | 2025-07-21 |
| Est. Completion | 2026-05-11 |
| Phase | Phase 4 |
What NCT07089706 shows while recruiting
NCT07089706 is an interventional study that assigns participants to a tested intervention. The registered 832 participants enrollment target is mid-sized for trials with a published cap, below the 38,462-participant average among 298 other COVID-19 trials with a reported enrollment target (98% lower).
The record links to 1 condition, with COVID-19 appearing as the primary indexed condition, and to 1 intervention - of which mRNA-1283.251 Variant-containing Formulation is the first listed.
NCT07089706 lists 5 locations in 4 states (Louisiana, Georgia, Mississippi).
Frequently Asked Questions
What is clinical trial NCT07089706 about?
NCT07089706 is a clinical study titled "A Study to Evaluate the Immunogenicity and Safety of mRNA-1283 COVID-19 Variant-containing Formulations". The purpose of this study is to evaluate the immunogenicity and safety of the recommended variant-containing formulations of mRNA-1283 COVID-19 vaccine (mNEXSPIKE®) within the current epidemiological environment.
What is the current status of trial NCT07089706?
This trial is currently recruiting. It is a Phase 4 study. The enrollment target is 832 participants. The study started on 2025-07-21. Estimated completion is 2026-05-11.
What conditions does trial NCT07089706 study?
This clinical trial studies the following conditions: COVID-19.
What interventions are being tested in trial NCT07089706?
The interventions under investigation include: mRNA-1283.251 Variant-containing Formulation (BIOLOGICAL).
Who is sponsoring clinical trial NCT07089706?
This trial is sponsored by ModernaTX, which has 90 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07089706 being conducted?
This trial has 5 study locations across Georgia, Louisiana, Mississippi, Oklahoma. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for COVID-19
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT07089706's enrollment target sits among peer trials
832 85th of 298 higher than 214 of 298 other COVID-19 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other COVID-19 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Pilot Clinical Evaluation of Astepro® Nasal Spray for Management of Early SARS-CoV-2 Infection
RECRUITING · Phase 4
-
Impact of Immunosuppression Adjustment on COVID-19 Vaccination Response in Kidney Transplant Recipients
RECRUITING · Phase 4
-
Comparative Immunogenicity of Respiratory Virus Vaccines (CIRV2) Study
RECRUITING · Phase 4
-
COVID-19 Reactogenicity
ACTIVE NOT RECRUITING · Phase 4
-
Impact of Reactogenicity of the 2024-2025 COVID-19 Vaccines on Health Care Workers and First Responders in the United States
ACTIVE NOT RECRUITING · Phase 4
-
Vitamin D Supplementation in the Prevention and Mitigation of COVID-19 Infection
ACTIVE NOT RECRUITING · Phase 4
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06910553 · 832 participants
IBD Pregnancy Registry
- NCT05067283 · 830 participants · Phase 1
A Study of Calderasib (MK-1084) in KRAS Mutant Advanced Solid Tumors (MK-1084-001)
- NCT06592924 · 830 participants · Phase 3
Docetaxel to Androgen Receptor Pathway Inhibitors in Patients With Metastatic Castration Sensitive Prostate Cancer and Suboptimal PSA Response
- NCT06868277 · 830 participants · Phase 3
A Global Phase III Study of Rilvegostomig or Pembrolizumab Monotherapy for First-Line Treatment of PD-L1-high Metastatic Non-small Cell Lung Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI